$30.15−1.44 (−4.56%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Agios Pharmaceuticals (AGIO) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
2 figures withheld by our checks. Each blank figure names its reason.
Business engineGrowing fast: revenue compounds ~56.0%/yr (FY22→FY25), net margin −764.0%. Worth your attention in FY25: Capex step-up ($4.3M). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲48.0%
54.0
FY22→FY25CAGR +56.0%/yr
Net income ($M)—
−412.8
FY21→FY25CAGR —
Free cash flow ($M)▲3.6%
−377.3
capex stepped upCAGR —
Diluted EPS—
−7.12
buyback-liftedCAGR —
What the receipts whisper · what a headline number hides
Share count
−4.1%
60.4mn → 58.0mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex step-up
$4.3M
▲156% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-764¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Net margin -764.0% is below the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 140.8 | 54.0 | 36.5 | 26.8 | 14.2 | 0.0 | ▲48.0% | +56.0% (22→25) |
Cost of revenue | 8.7 | 6.3 | 4.2 | 2.9 | 1.7 | 0.0 | ▲52.3% | +55.0% (22→25) |
Gross profit | 132.1 | 47.7 | 32.3 | 23.9 | 12.5 | —A | ▲47.5% | +56.1% |
Research & development | 343.4 | 339.5 | 301.3 | 295.5 | 279.9 | 257.0 | ▲12.7% | +7.2% |
Selling, general & admin | 208.0 | 180.3 | 156.8 | 119.9 | 121.7 | 121.4 | ▲15.0% | +10.4% |
Total operating expenses | 551.4 | 519.8 | 458.1 | 415.4 | 401.6 | 378.4 | ▲13.5% | +8.3% |
Operating incomefeeds ROC rank | −419.3 | −472.1 | −425.7 | −391.5 | −389.0 | −378.4 | ▼10.9% | — |
Other income, net | 45.7 | 58.3 | 1,143.7 | 39.4 | 157.2 | 21.9 | — | — |
Pretax income | −373.6 | −413.8 | 718.0 | −352.1 | −231.8 | −356.5 | — | — |
Income tax | — | −1.0 | 44.2 | 0.0 | 0.0 | — | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −372.9 | −412.8 | 673.7 | −352.1 | −231.8 | 1,604.7 | — | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −6.33 | −7.12 | 11.64 | −6.33 | −4.23 | 26.55 | — | — |
Diluted shares (mn) | 59.71 | 57.97 | 57.89 | 55.65 | 54.79 | 60.45 | ▲0.1% | −1.0% |
| Margins | ||||||||
Gross margin90th pct in Healthcare | 93.8% | 88.3% | 88.6% | 89.3% | 88.0% | —A | ▼0.3pp | +0.2pp |
Operating margin | −297.7% | −873.9% | −1166.5% | −1459.5% | −2732.1% | — | ▲292.6pp | +1858.2pp |
Net margin6th pct in Healthcare | −264.8% | −764.0% | 1845.9% | −1312.6% | −1627.8% | — | ▼2609.9pp | +863.8pp |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
5 more years of statements and CSV export are on Premium, and 10 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Agios Pharmaceuticals' revenue last fiscal year?
Agios Pharmaceuticals reported revenue of $54.0M in fiscal 2025, up 48.0% from fiscal 2024.
What was Agios Pharmaceuticals' net income?
Agios Pharmaceuticals reported net income of −$412.8M in fiscal 2025, a net margin of −764.0%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

